Related Experiment Videos
Tegaserod for constipation-predominant irritable bowel syndrome
Pramodini B Kale-Pradhan1, Sheila M Wilhelm
1Department of Pharmacy Practice, Wayne State University, Detroit, Michigan 48236-2172, USA. pkale@wayne.edu
Pharmacotherapy
|January 27, 2007
Summary
Tegaserod effectively treats women with constipation-predominant irritable bowel syndrome (IBS) by stimulating serotonin receptors to improve gut motility and reduce pain. It is generally well-tolerated, though severe diarrhea requires discontinuation.
Area of Science:
- Gastroenterology
- Pharmacology
Background:
- Constipation-predominant irritable bowel syndrome (IBS) significantly impacts women's quality of life.
- Current treatment options for IBS are limited, necessitating effective therapeutic agents.
Purpose of the Study:
- To evaluate the efficacy and safety of tegaserod for treating constipation-predominant IBS.
- To assess the drug's mechanism of action and patient tolerability.
Main Methods:
- Review of clinical studies on tegaserod's effects on gastrointestinal symptoms.
- Analysis of pharmacokinetic and pharmacodynamic data across different patient demographics.
- Assessment of adverse event profiles compared to placebo.
Main Results:
- Tegaserod, a 5-hydroxytryptamine (5-HT4) receptor agonist, enhances peristalsis and fluid secretion.
- The drug effectively alleviates abdominal pain, discomfort, and normalizes bowel habits in IBS patients.
- Tegaserod demonstrated a favorable safety profile, comparable to placebo, with manageable side effects.
Conclusions:
- Tegaserod is a safe and effective treatment option for women with constipation-predominant IBS.
- The drug's mechanism involves modulating gut motility and visceral sensitivity.
- Patients experiencing severe diarrhea should discontinue tegaserod treatment.
Related Concept Videos
01:21Drugs for Treatment of Constipation-Predominant IBS
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
01:17Drugs for Treatment of Diarrhea-Predominant IBS
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
01:23Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
01:20Drugs Affecting GI Tract Motility: Other Laxatives
Laxatives are primarily used to alleviate constipation, a common gastrointestinal disorder characterized by infrequent bowel movements and difficulty passing stools. They work by various mechanisms to increase the volume or frequency of bowel movements. The primary modes of action of laxatives include increasing stool bulk, softening the stool, stimulating intestinal motility, and osmotically drawing water into the intestines.
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
01:23Irritable Bowel Syndrome
DefinitionIrritable bowel syndrome (IBS) is a functional gastrointestinal disorder characterized by recurrent combinations of abdominal pain, bloating, diarrhea, or constipation.Pathophysiology of irritable bowel syndromeIts pathophysiology is multifactorial, involving disturbances in motility, sensory processing, microbial balance, barrier integrity, and gut–brain communication. These mechanisms interact to produce symptoms that vary across IBS subtypes.Altered Motility PatternsDisordered...
01:17Irritable Bowel Syndrome I: Introduction
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...